LGVN (Longeveron Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LGVN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-25 | Nirav S. Jhaveri | Chief Financial Officer | A | — | — |
| 2026-08-21 | Deborah Ascheim | Director | A | — | — |
| 2026-08-21 | Devin Blass | CTO & SVP of CMC | A | — | — |
| 2026-08-21 | George A. Paletta Jr. | Director | A | — | — |
| 2026-08-21 | Rock Soffer | Director | A | — | — |
| 2026-08-21 | Roger Joseph Hajjar | Director | A | — | — |
| 2026-08-21 | Arjun JJ Desai | Director | A | — | — |
| 2026-08-21 | Paul T Lehr | General Counsel, Secretary | A | — | — |
| 2026-08-21 | Nataliya Agafonova | Chief Medical Officer | A | — | — |
| 2026-08-21 | Leah Rush Cann | Director | A | — | — |
| 2026-08-21 | Joshua Hare | Chief Scientific Officer | A | — | — |
| 2026-08-21 | Ursula Ungaro | Director | A | — | — |
| 2026-07-08 | Joshua Hare | Chief Scientific Officer | A | — | — |
| 2026-07-06 | Stephen H Willard | Chief Executive Officer | F | — | — |
| 2026-07-06 | Paul T Lehr | General Counsel, Secretary | F | — | — |
| 2026-07-06 | Lisa Locklear | Chief Financial Officer | F | — | — |
| 2026-07-06 | Nataliya Agafonova | Chief Medical Officer | F | — | — |
| 2026-07-06 | Devin Blass | CTO & SVP of CMC | F | — | — |
| 2026-05-05 | Nataliya Agafonova | Chief Medical Officer | A | — | — |
| 2026-05-05 | Stephen H Willard | Chief Executive Officer | A | — | — |
| 2026-05-05 | Paul T Lehr | General Counsel, Secretary | A | — | — |
| 2026-05-05 | Lisa Locklear | Chief Financial Officer | A | — | — |
| 2026-05-05 | Devin Blass | CTO & SVP of CMC | A | — | — |
| 2026-04-03 | Lisa Locklear | Chief Financial Officer | F | — | — |
| 2026-04-03 | Devin Blass | CTO & SVP of CMC | F | — | — |
| 2026-04-03 | Nataliya Agafonova | Chief Medical Officer | F | — | — |
| 2026-04-03 | Stephen H Willard | Chief Executive Officer | F | — | — |
| 2026-04-03 | Paul T Lehr | General Counsel, Secretary | F | — | — |
| 2026-03-13 | Stephen H Willard | Chief Executive Officer | MIXED | — | — |
| 2026-01-06 | James Nathaniel Powell | Chief Executive Officer | F | — | — |
| 2026-01-06 | Devin Blass | CTO & SVP of CMC | F | — | — |
| 2026-01-06 | Nataliya Agafonova | Chief Medical Officer | F | — | — |
| 2026-01-06 | Lisa Locklear | Chief Financial Officer | F | — | — |
| 2026-01-06 | Paul T Lehr | General Counsel, Secretary | F | — | — |
| 2025-10-27 | George A. Paletta Jr. | Director | A | — | — |
| 2025-10-03 | Paul T Lehr | General Counsel, Secretary | F | — | — |
| 2025-10-03 | Devin Blass | CTO & SVP of CMC | F | — | — |
| 2025-10-03 | Lisa Locklear | Chief Financial Officer | F | — | — |
| 2025-10-03 | James Nathaniel Powell | Chief Executive Officer | F | — | — |
| 2025-10-03 | Nataliya Agafonova | Chief Medical Officer | F | — | — |
| 2025-10-01 | James Nathaniel Powell | Chief Executive Officer | A | — | — |
| 2025-08-13 | Khoso Baluch | Director | Buy | — | — |
| 2025-08-13 | Lisa Locklear | Chief Financial Officer | Buy | — | — |
| 2025-07-17 | Richard N Kender | Director | A | — | — |
| 2025-07-17 | Ursula Ungaro | Director | A | — | — |
| 2025-07-17 | Neha J. Motwani | Director | A | — | — |
| 2025-07-17 | Rock Soffer | Director | A | — | — |
| 2025-07-17 | Roger Joseph Hajjar | Director | A | — | — |
| 2025-07-17 | Mohamed Wa'el Ahmed Hashad | Chief Executive Officer | A | — | — |
| 2025-07-17 | Joshua Hare | Chief Scientific Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Scientific Officer | 161,315 | — |
| — | General Counsel, Secretary | 86,142 | — |
| — | Chief Executive Officer | 77,168 | — |
| — | Chief Medical Officer | 71,691 | — |
| — | CTO & SVP of CMC | 71,174 | — |
| — | Director | 66,937 | — |
| — | Chief Financial Officer | 44,318 | — |
| — | Chief Executive Officer | 42,090 | — |
| — | Chief Financial Officer | 30,000 | — |
| — | Director | 26,203 | — |
| — | Chief Executive Officer | 12,559 | — |
| — | Director | 7,700 | — |
| — | Director | 7,000 | — |
| — | Director | 6,900 | — |
| — | Director | 5,252 | — |
| — | Director | 3,600 | — |
| — | Director | 3,600 | — |
| — | Director | 3,600 | — |
| — | Director | 3,300 | — |
| — | Director | 3,300 | — |
| — | Director | 3,024 | — |
| — | CEO | 1,339 | — |
| — | CFO and Treasurer | 523 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LGVN quote page; the site-wide leaderboard is on the insider transactions hub.